



## SMS Lifesciences India Limited

**Registered & Corporate Office :**

Plot No. 19-III, Road No. 71,  
Opp. Bharatiya Vidya Bhavan Public School,  
Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.  
Tel : +91-040-6628 8888, Fax : +91-40-2355 1401  
CIN : L74930TG2006PLC050223  
Email : info@smslife.in, Website : www.smslife.in

August 21, 2020

To

**BSE Limited,**

Listing Department, P J Towers,

Dalal Street,

Mumbai – 400 001.

**Scrip code: 540679**

Through: BSE Listing Center

**National Stock Exchange of India Limited,**

Listing Department, "Exchange Plaza",

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

**Trading Symbol: SMSLIFE**

Through: NEAPS

**SUB: OUTCOME OF THE BOARD MEETING [financial results of Q1-FY 2020-21]**

**Ref: Regulation 33 read with sub-para 4 & 12 of Para "A" of Part "A" of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e. August 21, 2020, have *inter-alia* considered and approved

- ✦ The un-audited [Standalone and Consolidated] financial results for the quarter ended June 30, 2020, as recommended by the Audit Committee.
- ✦ Holding the 14<sup>th</sup> Annual General Meeting on September 30, 2020.

In this regard, we are enclosing herewith a copy of un-audited [Standalone and Consolidated] financial results for the quarter ended June 30, 2020 along with the Limited Review Reports received from the Statutory Auditors of the Company on the said results.

The meeting of the Board commenced at **12.30 pm** and concluded at **5.00 pm**.

**For SMS Lifesciences India Limited**

  
**Trupin Ranjan Mohanty**  
Company Secretary



[Enclosed: Quarterly results along with Limited Review Reports]

**SMS LIFESCIENCES INDIA LIMITED**

(CIN: L74930TG2006PLC050223)


Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Standalone Statement of Un Audited Financial Results for the Quarter Ended 30th June, 2020**

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Year ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		(Un Audited)	(Audited)	(Un Audited)	(Audited)
1	Revenue From Operations	5,477.76	4,625.28	9,271.50	25,692.41
2	Other Income	7.75	50.26	27.43	188.31
3	<b>Total Revenue</b>	<b>5,485.51</b>	<b>4,675.54</b>	<b>9,298.93</b>	<b>25,880.72</b>
4	<b>Expenses</b>				
	(a) Cost of materials consumed	2,540.82	3,105.53	6,184.92	15,575.16
	(b) Changes in inventories	669.22	(752.19)	218.77	629.28
	(c) Manufacturing Expenses	758.64	1,015.34	1,100.03	3,755.92
	(d) Employee Benefits Expense	528.55	599.75	544.58	2,327.02
	(e) Finance costs	118.21	114.29	141.29	508.88
	(f) Depreciation and amortisation expense	178.57	189.40	175.84	724.39
	(g) Other expenses	332.87	286.33	257.88	1,026.31
	<b>Total Expenses - (a to g)</b>	<b>5,126.88</b>	<b>4,558.45</b>	<b>8,623.31</b>	<b>24,546.96</b>
5	<b>Profit before Exceptional and Extraordinary Items and Tax (3-4)</b>	<b>358.63</b>	117.09	675.62	1,333.76
6	Exceptional items	-	-	-	-
7	<b>Profit before Extraordinary Items and Tax (5-6)</b>	<b>358.63</b>	117.09	675.62	1,333.76
8	Extraordinary Items	-	-	-	-
9	<b>Profit before Tax (7-8)</b>	<b>358.63</b>	117.09	675.62	1,333.76
10	Tax Expenses				
	(1) Current Tax	100.00	(40.39)	200.00	325.00
	(2) Deferred Tax	7.21	10.37	28.75	94.04
		<b>107.21</b>	<b>(30.02)</b>	<b>228.75</b>	<b>419.04</b>
11	<b>Net Profit / (Loss) for the Period (9-10)</b>	<b>251.42</b>	147.11	446.87	914.72
12	<b>Other Comprehensive Income/(Loss) (OCI):</b> Items that will not be reclassified to statement of Profit & Loss				
	Remeasurements of post-employment benefit obligations	(6.81)	(38.32)	(2.22)	(45.63)
13	Total Other Comprehensive Income/(Loss) before related Tax	(6.81)	(38.32)	(2.22)	(45.63)
14	Income Tax effect on the above	(1.98)	(11.16)	(0.65)	(13.29)
15	Other Comprehensive Income/(Loss) after tax for the Year (13-14)	(4.83)	(27.16)	(1.57)	(32.34)
16	<b>Total comprehensive Income for the period/year (11+15)</b>	<b>246.59</b>	119.95	445.30	882.38
17	Earnings Per Equity Share of Rs.10/ each) (not annualised)				
	(a) Basic	8.32	4.87	14.78	30.26
	(b) Diluted	8.32	4.87	14.78	30.26
18	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33
19	Other Equity excluding Revaluation Reserve				11,023.24





**Notes:**

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 21st August, 2020 and have been approved by the Board of Directors at its meeting held on 21st August, 2020.
- 2 Results for the quarter ended 30th June, 2020 were subjected to 'Limited Review' by the Auditors and their report contains no qualifications.
- 3 The standalone audited financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 4 The figures for the quarter ended 31st March 2020 are the balancing figures between audited figures in respect of full financial year upto 31st March, 2020 and the unaudited published year to date figures upto 31st December, 2019, being the date of the end of the third quarter of the financial year which were subjected to limited review.
- 5 Sales for the quarter ended June 30th, 2020 has increased by 19% as compared to previous quarter ended March 31st, 2020 whereas revenue has decreased by 40% compared to the corresponding quarter ended June 30th, 2019 due to NDMA issue in Ranitidine Hcl. The company is also focusing to manufacture and sell other new molecules developed by its own R&D along with few contract manufacturing co-partners resulting in increasing the revenues as well as margins. In addition to this the Company is evaluating import substitution products and opportunities arising out of COVID-19.
- 6 The Company has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the company will continue to closely monitor for any material changes to future economic conditions.
- 7 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
- 8 Figures of previous period have been regrouped / rearranged wherever necessary to confirm to the current period's classification.

For SMS Lifesciences India Limited



Place: Hyderabad  
Date : 21-08-2020

TVVSN Murthy  
Managing Director  
DIN : 00465198

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

**Review Report to  
The Board of Directors  
SMS Lifesciences India Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of SMS Lifesciences India Limited ("the Company"), for the quarter ended 30<sup>th</sup> June 2020 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements is free of material misstatement. A review of the interim financial information consists of making inquires primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 21-08-2020

UDIN: 20026548AAAACO1324

For Rambabu & Co.,  
Chartered Accountants  
Reg. No.002976S

  
GVL Prasad  
Partner  
M. No. 026548





**SMS LIFESCIENCES INDIA LIMITED**

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Consolidated Statement of Un Audited Financial Results for the Quarter Ended 30th June, 2020**

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Year ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		(Un Audited)	(Audited)	(Un Audited)	(Audited)
1	Revenue From Operations	5,474.90	4,598.54	9,184.13	26,078.12
2	Other Income	30.29	86.82	27.44	228.08
3	<b>Total Revenue</b>	<b>5,505.19</b>	<b>4,685.36</b>	<b>9,211.57</b>	<b>26,306.20</b>
4	<b>Expenses</b>				
	(a) Cost of materials consumed	2,459.73	3,049.56	5,893.18	14,704.39
	(b) Changes in inventories	619.43	(840.12)	232.06	1,083.68
	(c) Manufacturing Expenses	807.32	1,062.87	1,168.31	4,029.75
	(d) Employee Benefits Expense	606.26	674.63	613.19	2,656.31
	(e) Finance costs	118.70	115.14	141.23	513.72
	(f) Depreciation and amortisation expense	194.76	204.57	191.26	786.15
	(g) Other expenses	342.62	291.64	264.49	1,065.39
	<b>Total Expenses - (a to g)</b>	<b>5,148.82</b>	<b>4,558.29</b>	<b>8,503.72</b>	<b>24,839.39</b>
5	<b>Profit before Exceptional and Extraordinary Items and Tax (3-4)</b>	<b>356.37</b>	<b>127.07</b>	<b>707.85</b>	<b>1,466.81</b>
6	Exceptional items	-	-	-	-
7	<b>Profit before Extraordinary Items and Tax (5-6)</b>	<b>356.37</b>	<b>127.07</b>	<b>707.85</b>	<b>1,466.81</b>
8	Extraordinary Items	-	-	-	-
9	<b>Profit before Tax (7-8)</b>	<b>356.37</b>	<b>127.07</b>	<b>707.85</b>	<b>1,466.81</b>
10	Tax Expenses				
	(1) Current Tax	101.00	(40.39)	209.00	369.61
	(2) Deferred Tax	7.11	10.22	26.89	78.88
		<b>108.11</b>	<b>(30.17)</b>	<b>235.89</b>	<b>448.49</b>
11	<b>Net Profit / (Loss) after taxes</b>	<b>248.26</b>	<b>157.24</b>	<b>471.96</b>	<b>1,018.32</b>
12	<b>Other Comprehensive Income/(Loss) (OCI):</b>				
	Items that will not be reclassified to statement of Profit & Loss				
	Remeasurements of post-employment benefit obligations	(6.44)	(41.14)	(0.92)	(6.44)
13	Total Other Comprehensive Income/(Loss) before related Tax	(6.44)	(41.14)	(0.92)	(6.44)
14	Income Tax effect on the above	(1.88)	(11.94)	(0.28)	(1.88)
15	Other Comprehensive Income/(Loss) after tax for the Year (15+16-17)	(4.56)	(29.20)	(0.64)	(4.56)
16	<b>Total comprehensive Income for the period/year (14+18)</b>	<b>243.70</b>	<b>128.04</b>	<b>471.32</b>	<b>1,013.76</b>
17	Earning Per Equity Share (of Rs.10/ each) (not annualised)				
	(a) Basic	8.21	5.20	15.61	33.68
	(b) Diluted	8.21	5.20	15.61	33.68
18	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33
19	Other Equity excluding Revaluation Reserve				11,270.98



**Notes:**

- 1 The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 21st August, 2020 and have been approved by the Board of Directors at its meeting held on 21st August, 2020.
- 2 Results for the quarter ended 30th June, 2020 were subjected to 'Limited Review' by the Auditors and their report contains no qualifications.
- 3 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 4 The figures for the quarter ended 31st March, 2020 are the balancing figures between audited figures in respect of full financial year upto 31st March, 2020 and the unaudited published year to date figures upto 31st December, 2019 being the date of the end of the third quarter of the financial year which were subjected to limited review.
- 5 Sales for the quarter ended June 30th, 2020 has increased by 20% as compared to previous quarter ended March 31st, 2020 whereas revenue has decreased by 40% compared to the corresponding quarter ended June 30th, 2019 due to NDMA issue in Ranitidine Hcl. The company is also focusing to manufacture and sell other new molecules developed by its own R&D along with few contract manufacturing co-partners resulting in increasing the revenues as well as margins. In addition to this the Company is evaluating import substitution products and opportunities arising out of COVID-19.
- 6 The Consolidated un audited financial results include the un audited financial results of Mahi Drugs Private Limited a wholly owned subsidiary
- 7 The Group is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
- 8 The Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Group will continue to closely monitor for any material changes to future economic conditions.
- 9 Figures of previous period have been regrouped / rearranged wherever necessary to confirm to the current period's classification.

For SMS Lifesciences India Limited

Place: Hyderabad  
Date : 21-08-2020



  
TVVSN Murthy  
Managing Director  
DIN : 00465198



**Independent Auditor's Review Report on review of Interim Consolidated Financial Results**

To the Board of Directors of  
SMS Lifesciences India Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of SMS Lifesciences India Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30<sup>th</sup> June, 2020 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following subsidiaries

a. M/s. Mahi Drugs Private Limited



**RAMBABU & CO.,**  
**CHARTERED ACCOUNTANTS**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiaries which have not been reviewed by us, whose interim financial statements / financial information reflect total revenue of Rs. 365.62 lakhs, total net profit after tax of Rs. 2.88 lakhs and total comprehensive income of Rs. 3.15 lakhs for the Quarter ended June 30, 2020, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad

Date: 21-08-2020

UDIN: 20026548AAAACP1808

For Rambabu &amp; Co.,

Chartered Accountants

Reg. No.002976S

  
GVL Prasad

Partner

M. No. 026548

